Located in Princeton, N.J., Derma Sciences has gained a stellar reputation as a global manufacturer and marketer of advanced wound care products with MEDIHONEY showcasing Derma’s technology. MEDIHONEY, a honey–based product that treats and manages wounds and burns, is a state-of-the-art product and has been produced throughout the world.
It was announced today that Derma Sciences will list their common stock on the NASDAQ. This is a major move for the New Jersey Company that will enhance its future and allow investors to take notice.
One of the main reasons Derma Sciences was able to make such a move is the tireless work of their CEO Ed Quilty. Quilty is a known name in the industry and has been CEO of Derma Sciences since 1996. He has been instrumental in helping the company evolve to the successful state it is in today.
Prior to leading Derma, Quilty was the Chairman of the Board of Palatin Technologies, Inc., a publicly traded biopharmaceutical company specializing in peptide drug design for diagnostic and therapeutic agents from November, 1995 until May, 2000.
Quilty has been a leader in the healthcare industry for over 30 years. He continues to take Derma Sciences to new heights and the move to the NASDAQ is just one more example that this is a company on the move.
When asked about the effect the move to the NASDAQ will have on Derma’s future, Quilty was quoted as saying, “The NASDAQ listing represents a significant step for Derma Sciences that will provide increased visibility and should result in improved liquidity for our shares.”
Let us hear your thoughts below: